Swecrit Biobank - Blood Samples From Critically Ill Patients and Healthy Controls
NCT ID: NCT04974775
Last Updated: 2025-05-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
8500 participants
OBSERVATIONAL
2014-06-30
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cellular-Mediated Immunity in COVID-19
NCT04746521
Controls and Healthy Vasculature Initiative
NCT05403151
Blood Collection In Healthy Adult Volunteers To Obtain Serum For Use In Serum Bactericidal Activity Assay Development
NCT00401232
Collection and Distribution of Biospecimens for Novel Research Uses
NCT03848962
Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay
NCT01750203
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Diagnoses, disease course, treatment results and survival are prospectively collected from all critically ill patients in the Patient Administrative System for Intensive Care Units (PASIVA). PASIVA is the portal by which collected laboratory and physiological data are entered into the Swedish Intensive Care Register (SIR). Further data are collected retrospectively from other health-related registers, such as the Swedish Population Register, the International Cardiac Arrest Registry (INTCAR), The Swedish CPR Registry, the Swedish Trauma Registry (SweTrau), and the Regional quality register Covid-IR (covid19 disease).
Specifically for the covid19-cohort, detailed face-to-face follow-up will be performed of all survivors at 3 \& 12 months and a telephone interview after 3 years. Questionnaires (see below) will be sent to patients prior to the follow-up. Questions about well-being in general, quality-of-life, sleeping disorders, psychological and psychiatric problems will be addressed.
Collected blood samples in the ICU are processed by clinical chemistry at each participating hospital and frozen specimens of whole blood, serum, and plasma (200 ul aliquots) are sent to the biobank BD-47 in Region Skane for long-term storage (maximum 20 years).
The circulating substances and genetic markers, i.e. biomarkers that will be analyzed are: proteins (markers of inflammation, stress, infection, neurologic injury, myocardial injury and endothelial function) and other circulating substances in the blood (metabolomics), genes (DNA) from the entire genome, epigenetic changes (eg methylation status of DNA), gene fragments (eg secretory DNA), various forms of RNA such as micro-RNA \& longcoding RNA.
Research questions for future analyzes of collected samples are specified but subject to change, depending on progress and development in the specific research field of each study cohort.
1. Identification and use of biomarkers for assessment of severity of disease and trajectory over time in the ICU will be the main area of research.
2. Assessment of neurological prognosis and outcomes will be a common denominator in several studies.
3. Descriptive statistics and regression analyses will be performed in order to identify independent variables (biomarkers) of importance for prognosis and outcomes.
Inquiries to access the sample collection for research purpose can be sent to the central contacts listed below.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Critically Ill
Critically ill patients and patients in need of post-operative intensive care.
Blood collection
Sampling on admission to ICU (all patients)
Cardiac Arrest
Cardiac Arrest according to the ICD-10 I469 diagnosis.
Blood collection
Sampling on admission to ICU (all patients)
Blood collection, serial sampling
Additional sampling to admission samples in
1. the Cardiac Arrest group after 12 and 48 hours
2. the Covid-19 group on day 2 and 7 while in the ICU
3. the Covid-19 group after 3 and 12 months.
Sepsis
Sepsis according to the sepsis-3 criteria.
Blood collection
Sampling on admission to ICU (all patients)
Covid-19
Critically ill patients with a positive Covid-19 test.
Blood collection
Sampling on admission to ICU (all patients)
Blood collection, serial sampling
Additional sampling to admission samples in
1. the Cardiac Arrest group after 12 and 48 hours
2. the Covid-19 group on day 2 and 7 while in the ICU
3. the Covid-19 group after 3 and 12 months.
Influenza
Critically ill patients with a positive influenza test.
Blood collection
Sampling on admission to ICU (all patients)
Trauma
Critically ill patients after a severe traumatic event.
Blood collection
Sampling on admission to ICU (all patients)
Healthy controls
Healthy at the time of blood sampling
Blood collection
Sampling on admission to ICU (all patients)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood collection
Sampling on admission to ICU (all patients)
Blood collection, serial sampling
Additional sampling to admission samples in
1. the Cardiac Arrest group after 12 and 48 hours
2. the Covid-19 group on day 2 and 7 while in the ICU
3. the Covid-19 group after 3 and 12 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years or older
* covid19-verified (covid19-cohort)
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Region Skane
OTHER
Lund University
OTHER
Skane University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hans Friberg
Professor, Consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hans Friberg, MD, PhD
Role: STUDY_CHAIR
Skane University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Helsingborg Hospital
Helsingborg, , Sweden
Kristianstad Central Hospital
Kristianstad, , Sweden
Skane University Hospital
Lund, , Sweden
Skane University Hospital
Malmo, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lengquist M, Lundberg OHM, Spangfors M, Annborn M, Levin H, Friberg H, Frigyesi A. Sepsis is underreported in Swedish intensive care units: A retrospective observational multicentre study. Acta Anaesthesiol Scand. 2020 Sep;64(8):1167-1176. doi: 10.1111/aas.13647. Epub 2020 Jun 18.
Lundberg OHM, Lengquist M, Spangfors M, Annborn M, Bergmann D, Schulte J, Levin H, Melander O, Frigyesi A, Friberg H. Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness. Crit Care. 2020 Nov 4;24(1):636. doi: 10.1186/s13054-020-03351-1.
Thorgeirsdottir B, Levin H, Spangfors M, Annborn M, Cronberg T, Nielsen N, Lybeck A, Friberg H, Frigyesi A. Plasma proenkephalin A 119-159 and dipeptidyl peptidase 3 on admission after cardiac arrest help predict long-term neurological outcome. Resuscitation. 2021 Jun;163:108-115. doi: 10.1016/j.resuscitation.2021.04.021. Epub 2021 Apr 27.
Johnsson J, Bjornsson O, Andersson P, Jakobsson A, Cronberg T, Lilja G, Friberg H, Hassager C, Kjaergard J, Wise M, Nielsen N, Frigyesi A. Artificial neural networks improve early outcome prediction and risk classification in out-of-hospital cardiac arrest patients admitted to intensive care. Crit Care. 2020 Jul 30;24(1):474. doi: 10.1186/s13054-020-03103-1.
Arctaedius I, Wasselius J, Lang M, Drake M, Johnsson M, Friberg H, Leithner C, Kenda M, Lybeck A, Moseby-Knappe M. The semi-quantitative cardiac arrest brain ischemia (CABI) score for magnetic resonance imaging predicts functional outcome after cardiac arrest. Crit Care. 2025 Aug 20;29(1):373. doi: 10.1186/s13054-025-05595-1.
Didriksson I, Frigyesi A, Spangfors M, Leffler M, Reepalu A, Nilsson AC, Annborn M, Lybeck A, Friberg H, Lilja G. Long-term recovery in critically ill COVID-19 survivors: A prospective cohort study. Acta Anaesthesiol Scand. 2025 Jan;69(1):e14550. doi: 10.1111/aas.14550.
Didriksson I, Lengquist M, Spangfors M, Leffler M, Sievert T, Lilja G, Frigyesi A, Friberg H, Schiopu A. Increasing plasma calprotectin (S100A8/A9) is associated with 12-month mortality and unfavourable functional outcome in critically ill COVID-19 patients. J Intensive Care. 2024 Jul 9;12(1):26. doi: 10.1186/s40560-024-00740-4.
Arctaedius I, Levin H, Larsson M, Friberg H, Cronberg T, Nielsen N, Moseby-Knappe M, Lybeck A. 2021 European Resuscitation Council/European Society of Intensive Care Medicine Algorithm for Prognostication of Poor Neurological Outcome After Cardiac Arrest-Can Entry Criteria Be Broadened? Crit Care Med. 2024 Apr 1;52(4):531-541. doi: 10.1097/CCM.0000000000006113. Epub 2023 Dec 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SWECRIT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.